Extended Preclinical Safety, Efficacy and Stability Testing of a Live-attenuated Chikungunya Vaccine Candidate

PLoS Neglected Tropical Diseases

Volumn 9, Issue 9, 2015, Pages

  Plante, Kenneth S ^a   Rossi, Shannan L ^a   Bergren, Nicholas A ^a   Seymour, Robert L ^a   Weaver, Scott C ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHIKUNGUNYA VACCINE; UNCLASSIFIED DRUG; VACCINE; LIVE VACCINE; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG STABILITY; FEMALE; FOOT PAD; GENETIC STABILITY; HISTOPATHOLOGY; INFLAMMATION; MALE; MORTALITY; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SURVIVAL; TROPISM; VIREMIA; VIRUS LOAD; WEIGHT REDUCTION; ANIMAL; ANIMAL STRUCTURES; BODY WEIGHT; CHIKUNGUNYA FEVER; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; PATHOLOGY; PHYSIOLOGY; PRECLINICAL STUDY; SURVIVAL ANALYSIS; VIROLOGY; VIRULENCE;

ANIMAL STRUCTURES; ANIMALS; BODY WEIGHT; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FEMALE; IMMUNOCOMPROMISED HOST; MALE; MICE; SURVIVAL ANALYSIS; VACCINES, ATTENUATED; VIRAL LOAD; VIRAL VACCINES; VIRULENCE;

EID: 84943145123     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004007     Document Type: Article

References (43)

1. Kuhn RJ, Knipe DM, Howley PM, Togaviridae: The viruses and their replication. In: Fields' Virology, Fifth Edition. New York, NY: Lippincott, Williams and Wilkins; 2007. p. 1001–22.
2. Robinson MC, An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. Trans Royal Soc Trop Med Hyg. 1955;49:28.
3. Lumsden WH, An epidemic of virus disease in Southern Province, Tanganyika Territory, in 1952–53. II. General description and epidemiology. Trans R Soc Trop Med Hyg. 1955;49(1):33–57. Epub 1955/01/01. 14373835.
4. Ross RW, The Newala epidemic. III. The virus: isolation, pathogenic properties and relationship to the epidemic. J Hyg (Lond). 1956;54(2):177–91. 13346078.
5. Queyriaux B, Simon F, Grandadam M, Michel R, Tolou H, Boutin JP, Clinical burden of chikungunya virus infection. Lancet Infect Dis. 2008;8(1):2–3. Epub 2007/12/25. 18156079.
6. Lemant J, Boisson V, Winer A, Thibault L, Andre H, Tixier F, et al. Serious acute chikungunya virus infection requiring intensive care during the Reunion Island outbreak in 2005–2006. Critical care medicine. 2008;36(9):2536–41. 18679124. doi: 10.1097/CCM.0b013e318183f2d2
7. Chretien JP, Anyamba A, Bedno SA, Breiman RF, Sang R, Sergon K, et al. Drought-associated chikungunya emergence along coastal East Africa. Am J Trop Med Hyg. 2007;76(3):405–7. 17360859.
8. Gerardin P, Guernier V, Perrau J, Fianu A, Le Roux K, Grivard P, et al. Estimating Chikungunya prevalence in La Reunion Island outbreak by serosurveys: two methods for two critical times of the epidemic. BMC infectious diseases. 2008;8:99. Epub 2008/07/30. doi: 10.1186/1471-2334-8-99 PubMed Central PMCID: PMC2528011. 18662384
9. Arankalle VA, Shrivastava S, Cherian S, Gunjikar RS, Walimbe AM, Jadhav SM, et al. Genetic divergence of Chikungunya viruses in India (1963–2006) with special reference to the 2005–2006 explosive epidemic. J Gen Virol. 2007;88(Pt 7):1967–76. 17554030.
10. Ng LC, Tan LK, Tan CH, Tan SS, Hapuarachchi HC, Pok KY, et al. Entomologic and virologic investigation of Chikungunya, Singapore. Emerg Infect Dis. 2009;15(8):1243–9. PubMed Central PMCID: PMC2815960. doi: 10.3201/eid1508.081486 19751586
11. Grandadam M, Caro V, Plumet S, Thiberge JM, Souares Y, Failloux AB, et al. Chikungunya virus, southeastern France. Emerg Infect Dis. 2011;17(5):910–3. 21529410. doi: 10.3201/eid1705.101873
12. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, et al. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet. 2007;370(9602):1840–6. 18061059.
13. Leparc-Goffart I, Nougairede A, Cassadou S, Prat C, de Lamballerie X, Chikungunya in the Americas. Lancet. 2014;383(9916):514. 24506907. doi: 10.1016/S0140-6736(14)60185-9
14. Weaver SC, Forrester NL, Chikungunya: Evolutionary history and recent epidemic spread. Antiviral Res. 2015;120:32–9. Epub 2015/05/17. 25979669. doi: 10.1016/j.antiviral.2015.04.016
15. Weaver SC, Lecuit M, Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med. 2015;372(13):1231–9. Epub 2015/03/26. 25806915. doi: 10.1056/NEJMra1406035
16. Eckels KH, Harrison VR, Hetrick FM, Chikungunya virus vaccine prepared by Tween-ether extraction. Appl Microbiol. 1970;19(2):321–5. Epub 1970/02/01. PubMed Central PMCID: PMC376676. 4985431
17. Harrison VR, Eckels KH, Bartelloni PJ, Hampton C, Production and evaluation of a formalin-killed Chikungunya vaccine. J Immunol. 1971;107(3):643–7. Epub 1971/09/01. 4999088.
18. White A, Berman S, Lowenthal JP, Comparative immunogenicities of Chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures. Appl Microbiol. 1972;23(5):951–2. PubMed Central PMCID: PMC380477. 4624213
19. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Lupton HW, Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine. 1986;4(3):157–62. 3020820
20. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA, Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. The American journal of tropical medicine and hygiene. 2000;62(6):681–5. 11304054.
21. Gorchakov R, Wang E, Leal G, Forrester NL, Plante K, Rossi SL, et al. Attenuation of chikungunya virus vaccine strain 181/clone 25 is determined by two amino Acid substitutions in the e2 envelope glycoprotein. J Virol. 2012;86(11):6084–96. 22457519. doi: 10.1128/JVI.06449-11
22. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT, Chikungunya virus and prospects for a vaccine. Expert Rev Vaccines. 2012;11(9):1087–101. PubMed Central PMCID: PMC3562718. doi: 10.1586/erv.12.84 23151166
23. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat Med. 2010;16(3):334–8. PubMed Central PMCID: PMC2834826. doi: 10.1038/nm.2105 20111039
24. Chang LJ, Dowd KA, Mendoza FH, Saunders JG, Sitar S, Plummer SH, et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet. 2014. 25132507.
25. Brandler S, Ruffie C, Combredet C, Brault JB, Najburg V, Prevost MC, et al. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine. 2013;31(36):3718–25. 23742993. doi: 10.1016/j.vaccine.2013.05.086
26. Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak RJ, Thomas SJ, et al. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. The Lancet infectious diseases. 2015. Epub 2015/03/06. doi: 10.1016/S1473-3099(15)70043-5 25739878.
27. Volkova E, Frolova E, Darwin JR, Forrester NL, Weaver SC, Frolov I, IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells. Virology. 2008;377(1):160–9. 18501401. doi: 10.1016/j.virol.2008.04.020
28. Finkelstein Y, Faktor O, Elroy-Stein O, Levi BZ, The use of bi-cistronic transfer vectors for the baculovirus expression system. J Biotechnol. 1999;75(1):33–44. 10510857.
29. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, et al. Novel Chikungunya Vaccine Candidate with an IRES-Based Attenuation and Host Range Alteration Mechanism. PLoS Pathog. 2011;7(7):e1002142. Epub 2011/08/11. doi: 10.1371/journal.ppat.1002142 PPATHOGENS-D-10-00486 [pii]. 21829348; PubMed Central PMCID: PMC3145802.
30. Partidos CD, Weger J, Brewoo J, Seymour R, Borland EM, Ledermann JP, et al. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine. 2011;29(16):3067–73. PubMed Central PMCID: PMC3081687. doi: 10.1016/j.vaccine.2011.01.076 21300099
31. Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, et al. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine. 2012;30(31):4638–43. PubMed Central PMCID: PMC3372665. doi: 10.1016/j.vaccine.2012.04.099 22583812
32. Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, et al. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine. 2013;31(33):3353–60. PubMed Central PMCID: PMC3731778. doi: 10.1016/j.vaccine.2013.05.059 23727003
33. Guerbois M, Volkova E, Forrester NL, Rossi SL, Frolov I, Weaver SC, IRES-driven expression of the capsid protein of the Venezuelan equine encephalitis virus TC-83 vaccine strain increases its attenuation and safety. PLoS Negl Trop Dis. 2013;7(5):e2197. PubMed Central PMCID: PMC3649961. doi: 10.1371/journal.pntd.0002197 23675542
34. Rossi SL, Guerbois M, Gorchakov R, Plante KS, Forrester NL, Weaver SC, IRES-based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice. Virology. 2013;437(2):81–8. PubMed Central PMCID: PMC3767167. doi: 10.1016/j.virol.2012.11.013 23351391
35. Pandya J, Gorchakov R, Wang E, Leal G, Weaver SC, A vaccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuation. Vaccine. 2012;30(7):1276–82. PubMed Central PMCID: PMC3283035. doi: 10.1016/j.vaccine.2011.12.121 22222869
36. Weise WJ, Hermance ME, Forrester N, Adams AP, Langsjoen R, Gorchakov R, et al. A novel live-attenuated vaccine candidate for mayaro Fever. PLoS Negl Trop Dis. 2014;8(8):e2969. PubMed Central PMCID: PMCPMC4125120. doi: 10.1371/journal.pntd.0002969 25101995
37. Roy CJ, Adams AP, Wang E, Plante K, Gorchakov R, Seymour RL, et al. Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose. J Infect Dis. 2014;209(12):1891–9. PubMed Central PMCID: PMC4038141. doi: 10.1093/infdis/jiu014 24403555
38. Couderc T, Chretien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, et al. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog. 2008;4(2):e29. Epub 2008/02/20. PubMed Central PMCID: PMC2242832. doi: 10.1371/journal.ppat.0040029 18282093
39. Lennette EH, Lennette DA, Lennette ET, Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. Washington, D. C.: American Public Health Association.; 1995.
40. Sun C, Gardner CL, Watson AM, Ryman KD, Klimstra WB, Stable, high-level expression of reporter proteins from improved alphavirus expression vectors to track replication and dissemination during encephalitic and arthritogenic disease. J Virol. 2014;88(4):2035–46. PubMed Central PMCID: PMC3911548. doi: 10.1128/JVI.02990-13 24307590
41. Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, et al. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl Trop Dis. 2014;8(2):e2719. PubMed Central PMCID: PMC3930508. doi: 10.1371/journal.pntd.0002719 24587470
42. Gardner CL, Burke CW, Higgs ST, Klimstra WB, Ryman KD, Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate. Virology. 2012;425(2):103–12. 22305131. doi: 10.1016/j.virol.2011.12.020
43. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, et al. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature. 2010;468(7324):709–12. Epub 2010/12/03. 21124458. doi: 10.1038/nature09555